Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | GRK6 | P43250 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538984 | 0.87 | CXCL8 (0.57) | CXCL8TDP1AKR1B1PTGS2LMNA | |
| SCHEMBL2395880 | 0.85 | ALDH1A1 (0.41) | CXCL8GRK6LMNARAB9A | |
| SCHEMBL723768 | 0.83 | CXCL8 (0.56) | CXCL8TDP1AKR1B1PTGS2 | |
| SCHEMBL7827157 | 0.83 | AKR1B1 (0.67) | CXCL8TDP1AKR1B1PTGS2LMNA | |
| SCHEMBL28134586 | 0.82 | CXCL8 (0.54) | CXCL8TDP1AKR1B1PTGS2 | |
| SCHEMBL1154512 | 0.80 | CXCL8 (0.47) | CXCL8TDP1AKR1B1PTGS2LMNA | |
| SCHEMBL29533621 | 0.79 | CXCL8 (0.65) | CXCL8TDP1AKR1B1PTGS2LMNA | |
| SCHEMBL8645 | 0.79 | CXCL8 (0.65) | CXCL8TDP1AKR1B1PTGS2LMNA | |
| SCHEMBL15866869 | 0.78 | LMNA (0.38) | GRK6LMNARAB9A | |
| Fluoride SCHEMBL11183201 | 0.77 | CXCL8 (0.62) | CXCL8TDP1AKR1B1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CXCL8 3300/4885TDP1 4273/4885AKR1B1 734/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | CXCL8 3300/4885TDP1 4273/4885AKR1B1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.